An interventional study of Supervised exercise training and protein supplement in Type 2 Diabetes (T2DM), Obesity & Overweight and Sarcopenia, sponsored by German Diabetes Center. Not yet recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by German Diabetes Center · Not applicable, Interventional, and Supportive care
The goal of this clinical trial is to learn if supervised exercise training combined with a daily protein supplement can reduce the loss of muscle mass and muscle strength in adults with type 2 diabetes who have recently started treatment with semaglutide or tirzepatide. The main questions it aims to answer are:
Researchers will compare participants who take part in the exercise and protein program to participants who receive usual care only, to see if the program helps to preserve skeletal muscle during treatment-related weight loss.
All participants will:
Participants in the exercise and protein group will also:
Background
Glucagon-like peptide-1 receptor agonists (GLP-1RA) such as semaglutide and the dual GIP/GLP-1 receptor agonist tirzepatide are increasingly used in people with type 2 diabetes. They lower blood glucose and lead to substantial weight loss, often 15-20% of body weight. However, a relevant part of this weight loss consists of lean mass, including skeletal muscle. This is of particular concern in type 2 diabetes, because skeletal muscle is the main site of insulin-stimulated glucose uptake and people with type 2 diabetes already have an increased risk of low muscle mass and function (sarcopenia). It is still unclear whether the loss of muscle mass during GLP-1RA treatment also leads to a loss of muscle strength and physical function, and how it affects metabolic health.
Resistance exercise combined with adequate protein intake is an established strategy to preserve muscle mass and function during weight loss, and high-intensity interval training (HIIT) improves glucose control, insulin sensitivity and cardiorespiratory fitness. Current guidelines recommend combining GLP-1RA therapy with exercise and adequate protein intake, but this recommendation is based largely on extrapolation. No randomized trial has yet tested a structured, supervised combination of aerobic and hypertrophy-focused resistance training with protein supplementation in people with type 2 diabetes starting GLP-1RA therapy, while assessing muscle mass, muscle function and metabolic outcomes in detail.
Study design
COMPACT is a randomized, controlled, open-label, multicenter trial conducted at the German Diabetes Center (DDZ) in Düsseldorf and partner sites of the German Center for Diabetes Research (DZD). Adults with type 2 diabetes who have started semaglutide or tirzepatide within the previous eight weeks are randomly assigned in a 1:1 ratio to an exercise and protein intervention group or a control group. Randomization is stratified by sex and study center. GLP-1RA treatment is prescribed and managed exclusively by the participants' treating physicians and is not part of the study intervention. All participants receive a standardized lifestyle counselling session at the start of the study, covering a protein intake of at least 1.2 g per kg body weight per day and physical activity in daily life.
Intervention
Participants in the intervention group take part in a 24-week supervised training program with three sessions per week at the study center. The program alternates between three session types: full-body resistance training on machines at 70% of the one-repetition maximum, high-intensity interval training on a cycle ergometer, and a combined session of interval training and lower-body resistance training.
In addition, participants in the intervention group take 25 g of whey protein isolate per day, directly after each training session or in the morning on training-free days. Compliance is monitored by counting returned supplement sachets.
Study visits and assessments
Comprehensive assessments are performed at baseline and after 24 weeks, each over two consecutive days.
On the first day, participants come to the study center after an overnight fast. Body composition is measured by air displacement plethysmography (BodPod), and liver stiffness by transient elastography (FibroScan). Insulin sensitivity of the liver, adipose tissue and skeletal muscle is assessed with a two-step hyperinsulinemic-euglycemic clamp, combined with a stable isotope tracer (6,6-²H₂-glucose, non-radioactive) to measure endogenous glucose production. Energy expenditure and substrate oxidation are measured by indirect calorimetry at baseline and during both insulin steps. At participating centers, small samples of thigh muscle and abdominal fat tissue are taken before insulin infusion, and a second muscle sample is taken during the high-dose insulin step, to study mitochondrial function and molecular adaptations.
On the second day, magnetic resonance imaging (MRI) and spectroscopy are used to measure thigh muscle volume, lipids within the muscle, abdominal and whole-body lipid distribution, and liver lipid content. Muscle strength and physical function are assessed by isometric strength testing, handgrip strength, chair-stand, gait speed and balance tests. Maximal aerobic capacity is measured by cardiopulmonary exercise testing on a cycle ergometer.
Dietary intake, eating behavior, physical activity, quality of life and well-being are assessed by questionnaires and food diaries at baseline and at weeks 6, 12, 18 and 24. Protein intake is additionally estimated from urinary nitrogen excretion in 24-hour urine collections before both main study visits.
Data management and sample storage
Pseudonymized data from all centers are collected in a central electronic database (REDCap) at the coordinating center. The standardized DZD Core Data Set is collected at baseline and week 24. Participants may additionally choose to donate blood and urine samples to the DZD DiaMet Biobank under a separate consent.
Significance
COMPACT will show whether a supervised exercise and protein program can attenuate skeletal muscle mass and function during GLP-1RA-induced weight loss in people with type 2 diabetes, and whether better muscle preservation is linked to greater improvements in insulin sensitivity and metabolic health. The results may help to develop evidence-based recommendations for accompanying lifestyle measures in patients receiving these increasingly used medications.
10,371 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,406 are open to participants now.
This study's planned enrollment of 94 is above the median of 80 across 8,350 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →German Diabetes Center is the lead sponsor of 30 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants continue their GLP-1 receptor agonist therapy (semaglutide or tirzepatide) as prescribed by their treating physician and receive one standardized lifestyle counselling session on nutrition and physical activity at baseline. In addition, they take part in a 24-week supervised training program with three sessions per week at the study center, alternating between full-body resistance training, high-intensity interval training on a cycle ergometer, and a combined session. Training intensity is progressively increased and individually adjusted. Participants also take 25 g of whey protein isolate daily, directly after each training session or in the morning on training-free days.
Behavioral: Supervised exercise training · Dietary Supplement: protein supplement · Behavioral: Standardized lifestyle counseling
Participants continue their GLP-1 receptor agonist therapy (semaglutide or tirzepatide) as prescribed by their treating physician and receive one standardized lifestyle counselling session on nutrition and physical activity at baseline. They do not take part in the supervised training program and do not receive protein supplementation.
Behavioral: Standardized lifestyle counseling
Supervised exercise training at the study center, 3 sessions per week for 24 weeks (72 sessions), consisting of full-body resistance training (approx. 70% 1RM), high-intensity interval training on a cycle ergometer and a combined session. Training loads are progressively adjusted. Participants are required to attend at least 85% of sessions.
25 g whey protein daily for 24 weeks, taken after each training session and in the morning on non-training days. Compliance is monitored via returned sachets.
Also known as: Whey protein supplementation
A single standardized counselling session at baseline on dietary protein intake (≥1.2 g/kg body weight per day) and physical activity, delivered identically in both study arms.
Also known as: Usual Care
Change in Contractile Thigh Muscle Volume
Change in contractile thigh skeletal muscle volume (mL), assessed by magnetic resonance imaging (MRI). Contractile thigh muscle volume is defined as the sum of the bilateral anterior (quadriceps femoris, sartorius, tensor fasciae latae) and posterior (gluteal muscles, iliopsoas, adductors, hamstrings) thigh skeletal muscle volume minus intramuscular adipose tissue (IMAT) volume.
Time frame: Baseline to week 24
Percent Change in Contractile Thigh Skeletal Muscle Volume
Percent change in contractile thigh skeletal muscle volume from baseline to week 24, assessed by MRI. Contractile thigh muscle volume is defined as the sum of the bilateral anterior (quadriceps femoris, sartorius, tensor fasciae latae) and posterior (gluteal muscles, iliopsoas, adductors, hamstrings) thigh skeletal muscle volume minus intramuscular adipose tissue (IMAT) volume.
Time frame: Baseline and week 24
Change in Body Weight
Change in body weight (kg) from baseline to week 24, measured on a calibrated scale in light clothing and without shoes.
Time frame: Baseline and week 24
Change in Isometric Knee Extensor Strength
Change in maximal isometric knee extensor peak torque (Nm) from baseline to week 24, assessed at 60° knee flexion using an isometric dynamometer with Smartpanel software (highest value of 2-3 maximal voluntary trials).
Time frame: Baseline and week 24
Change in Isometric Knee Flexor Strength
Change in maximal isometric knee flexor peak torque (Nm) from baseline to week 24, assessed at 60° knee flexion using an isometric dynamometer with Smartpanel software (highest value of 2-3 maximal voluntary trials).
Time frame: Baseline and week 24
Change in 30-Second Chair Stand Test Performance
Change in the number of completed full stands within 30 seconds (arms crossed over the chest, no arm support) from baseline to week 24.
Time frame: Baseline and week 24
Change in Usual Gait Speed
Change in usual gait speed (m/s) from baseline to week 24, assessed by a 10-meter walk test at self-selected pace (faster of two trials).
Time frame: Baseline and week 24
Change in Handgrip Strength
Change in maximal handgrip strength (kg) from baseline to week 24, assessed using a hand dynamometer in a seated position with the elbow flexed at 90°.
Time frame: Baseline and week 24
Change in Standing Balance
Change in standing balance from baseline to week 24, assessed by a graded balance test battery (side-by-side, semi-tandem and tandem stand, each up to 10 s; followed by single-leg stance with eyes open, up to 30 s, if the tandem stand is completed). Hold time (s) is recorded for each position.
Time frame: Baseline and week 24
Change in Thigh Intramuscular Adipose Tissue Volume
Change in thigh intramuscular adipose tissue (IMAT) volume (mL) from baseline to week 24, assessed by MRI.
Time frame: Baseline and week 24
Change in Visceral Adipose Tissue Volume
Change in visceral adipose tissue volume (L) from baseline to week 24, assessed by whole-body MRI (6-point mDIXON).
Time frame: Baseline and week 24
Change in Subcutaneous Adipose Tissue Volume
Change in subcutaneous adipose tissue volume (L) from baseline to week 24, assessed by whole-body MRI (6-point mDIXON).
Time frame: Baseline and week 24
Change in Hepatic Lipid Content (¹H-MRS)
Change in hepatic lipid content (%) from baseline to week 24, assessed by single-voxel proton magnetic resonance spectroscopy (¹H-MRS).
Time frame: Baseline and week 24
Change in Liver Proton Density Fat Fraction (MRI-PDFF)
Change in liver proton density fat fraction (%) from baseline to week 24, assessed by quantitative MRI (6-echo Dixon).
Time frame: Baseline and week 24
Change in Fat Mass
Change in total body fat mass (kg) from baseline to week 24, assessed by air-displacement plethysmography (BodPod) or bioelectrical impedance analysis (BIA), depending on center-specific availability.
Time frame: Baseline and week 24
Change in Fat-Free Mass
Change in total body fat-free mass (kg) from baseline to week 24, assessed by air-displacement plethysmography (BodPod) or bioelectrical impedance analysis (BIA), depending on center-specific availability.
Time frame: Baseline and week 24
Change in Whole-Body Insulin Sensitivity
Change in whole-body insulin sensitivity from baseline to week 24, assessed as insulin-stimulated glucose disposal (M-value) during the hyperinsulinemic-euglycemic clamp.
Time frame: Baseline and week 24
Change in Liver Stiffness
Change in liver stiffness (kPa) from baseline to week 24, assessed by vibration-controlled transient elastography (FibroScan; median of 10 valid measurements).
Time frame: Baseline and week 24
Change in Absolute Maximal Oxygen Uptake (VO2max)
Change in absolute VO2max (mL/min) from baseline to week 24, assessed by symptom-limited incremental cardiopulmonary exercise testing (CPET) on a cycle ergometer.
Time frame: Baseline and week 24
Change in Relative Maximal Oxygen Uptake (VO2max)
Change in VO2max relative to body weight (mL/kg/min) from baseline to week 24, assessed by symptom-limited incremental cardiopulmonary exercise testing (CPET) on a cycle ergometer.
Time frame: Baseline and week 24
Change in Health-Related Quality of Life (SF-36)
Change in SF-36 domain scores (each 0-100; higher scores indicate better health status).
Time frame: Baseline and week 24
Change in Well-Being (WHO-5)
Change in WHO-5 Well-being Index (0-100; higher scores indicate better well-being).
Time frame: Baseline, weeks 6, 12, 18 and 24
Change in Habitual Physical Activity (Baecke Questionnaire)
Change in Baecke questionnaire work, sport and leisure-time activity indices.
Time frame: Baseline to week 24
Change in Alcohol Consumption (AUDIT-C)
Change in AUDIT-C score (0-12; higher scores indicate higher alcohol consumption).
Time frame: Baseline to week 24
Change in Energy and Macronutrient Intake
Change in total energy (kcal/day) and macronutrient intake (g/day), assessed by repeated food records and the EPIC-Potsdam Food Frequency Questionnaire.
Time frame: Baseline, weeks 6, 12, 18 and 24
Change in Food-Related Psychological Impact (Power of Food Scale)
Change in Power of Food Scale aggregate score (1-5; higher scores indicate greater responsiveness to the food environment).
Time frame: Baseline to week 24
Change in Food Cravings (Control of Eating Questionnaire)
Change in Control of Eating Questionnaire subscale scores (craving control, positive mood, craving for sweet, craving for savoury).
Time frame: Baseline, weeks 6, 12, 18 and 24
Adherence to the Supervised Training Program
Proportion of completed supervised training sessions out of 72 planned sessions, assessed by attendance records (Exercise and Protein Supplementation arm only).
Time frame: Weeks 1 to 24
Change in Resting and Insulin-Stimulated Energy Expenditure
Change in energy expenditure (kcal/day) in the basal state and during the low- and high-dose insulin steps of the clamp, assessed by indirect calorimetry.
Time frame: Baseline to week 24
Change in Substrate Oxidation and Metabolic Flexibility
Change in glucose and lipid oxidation rates (mg/kg/min) and respiratory quotient in the basal state and during the low- and high-dose insulin steps of the clamp, assessed by indirect calorimetry; metabolic flexibility defined as the change in respiratory quotient from basal to insulin-stimulated conditions.
Time frame: Baseline to week 24
Change in Protein Intake Estimated from Urinary Nitrogen Excretion
Change in 24-hour urinary nitrogen excretion (g/day) and estimated protein intake (g/kg/day) from baseline to week 24 (both arms).
Time frame: Baseline to week 24
Protein Supplement Compliance
Proportion of consumed protein supplement sachets, assessed by counting returned sachets (Exercise and Protein Supplementation arm only).
Time frame: Weeks 1 to 24
Change in Skeletal Muscle Mitochondrial Respiration
Change in ex vivo mitochondrial respiratory capacity (pmol O₂/s/mg wet weight) in permeabilized vastus lateralis muscle fibers, assessed by high-resolution respirometry (center-dependent).
Time frame: Baseline and week 24
Change in Adipose Tissue Mitochondrial Respiration
Change in ex vivo mitochondrial respiratory capacity in subcutaneous abdominal adipose tissue, assessed by high-resolution respirometry (center-dependent).
Time frame: Baseline and week 24
Change in Exercise Efficiency
Change in delta, gross and net exercise efficiency (%) during submaximal cycling at 30% and 50% Wmax, assessed by indirect calorimetry during the first and last supervised training session (Exercise and Protein Supplementation arm only).
Time frame: Week 1 and week 24
Change in Skeletal Muscle Mass Assessed by Bioelectrical Impedance Analysis
Change in whole-body skeletal muscle mass (kg) from baseline to week 24, assessed by bioelectrical impedance analysis (BIA). BIA is used at centers where air displacement plethysmography (BodPod) is unavailable; this outcome is therefore assessed only in participants measured by BIA, using the same device at baseline and week 24.
Time frame: Baseline to week 24
Change in Phase Angle Assessed by Bioelectrical Impedance Analysis
Change in whole-body phase angle (degrees) from baseline to week 24, assessed by bioelectrical impedance analysis (BIA) as an indicator of cell membrane integrity and muscle quality. BIA is used at centers where air displacement plethysmography (BodPod) is unavailable; this outcome is therefore assessed only in participants measured by BIA, using the same device at baseline and week 24.
Time frame: Baseline to week 24
Plan to share: Undecided — A decision on sharing individual participant data (IPD) has not yet been made. The steering committee will decide before the end of the study whether, and under which conditions, de-identified IPD can be made available to other researchers, in accordance with data protection regulations (GDPR). Aggregated study results will be published in peer-reviewed journals.
Start is estimated for Feb 2027; primary completion for Jan 2030, 35 months later.
Of 2,066 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 35 months is above that.
Counting every sponsor, half of 2,243 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Protein Supplement
German Diabetes Center